<DOC>
	<DOCNO>NCT02616185</DOCNO>
	<brief_summary>The study evaluate safety , pharmacokinetics pharmacodynamics increase dos vaccine-based immunotherapy regimen patient prostate cancer .</brief_summary>
	<brief_title>A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer ( PrCa VBIR )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histological cytological diagnosis prostate cancer Adequate bone marrow , kidney liver function Hormone sensitive relapse prostate cancer definitive local therapy ( biochemical relapse ) OR Progressive disease postsurgical castration androgen suppression therapy ( presecondary hormone CRPC ) OR Failed prior therapy secondary hormone ( e.g . enzalutamide , abiraterone ) document progressive disease ( postsecondary hormone CRPC ) Cancerrelated pain require schedule opioid narcotic control ECOG performance status great equal 2 Concurrent immunotherapy prostate cancer History active autoimmune disorder history inflammatory bowel disorder Current use implant electronic stimulation device For biochemically relapsed patient , concurrent use ADT orchiectomy know prior current evidence metastatic involvement distant organ For presecondary hormone patient , prior concurrent treatment secondary hormone ( e.g . enzalutamide , abiraterone ) metastasis organ system lymph node and/or bone For postsecondary hormone patient , concurrent treatment secondary hormone ( e.g . enzalutamide , abiraterone ) , metastasis liver brain</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>